Centre for Prevention of Stroke and Dementia, John Radcliffe Hospital, University of Oxford, Oxford, UK.
J Hypertens. 2019 Jun;37(6):1119-1125. doi: 10.1097/HJH.0000000000002033.
Vasodilating antihypertensives prevent stroke and potentially cerebral small vessel disease but their effects on cerebrovascular haemodynamics beyond blood pressure lowering are unclear.
We searched PubMed, Medline, Embase, Cinahl, Psychinfo, Health Business Elite and Health Management Information Consortium for randomized studies of vasodilating medications, compared to no treatment or nonvasodilators, that reported effects on cerebral blood flow (CBF), mean blood flow velocity (MFV) or cerebrovascular reactivity. Absolute and standardized mean differences (SMD) were combined by inverse-variance weighted fixed or random-effects meta-analysis stratified by study design, population characteristics and vasodilator class.
In 35 studies reporting 57 comparisons, there was a reduction in SBP (-4.13 mmHg, -7.55 to -0.71, P = 0.018) but no change in MFV (ΔMFV 1.11, confidence interval -0.93 to 3.14, P = 0.29, 23 comparisons). MFV increased in patients with underlying conditions (3.41, 0.24 to 6.57, P = 0.04) but not in healthy study participants (-1.27, -5.18 to 2.64, P = 0.68), with no differences by vasodilating drug class. Cerebral pulsatility index was reduced across all studies (Δ pulsatility index -0.04, -0.07 to -0.02, P = 0.001; Δ pulsatility index -SMD -0.32, -0.47 to -0.16, P < 0.001), except in studies reporting responses to single drug doses (Δ pulsatility index 0.00, -0.09 to -0.08, P = 0.93). Despite evidence of reporting and publication bias, there was an apparent consistent reduction in CBF with vasodilators (CBF-SMD -0.24, -0.46 to -0.02, P = 0.03) with a significant increase in cerebrovascular reactivity-SMD (0.48, 0.13-0.83, P = 0.007).
Despite reducing SBP, vasodilators did not significantly impair absolute CBF but improved cerebrovascular pulsatility and reactivity, suggesting therapeutic potential in preventing stroke and cerebral small vessel disease.
血管舒张降压药可预防中风和潜在的脑小血管疾病,但它们对降压以外的脑血管血液动力学的影响尚不清楚。
我们检索了 PubMed、Medline、Embase、Cinahl、Psychinfo、Health Business Elite 和 Health Management Information Consortium,以寻找比较血管舒张药物与无治疗或非血管舒张药物的随机研究,这些研究报告了对脑血流(CBF)、平均血流速度(MFV)或脑血管反应性的影响。通过逆方差加权固定或随机效应荟萃分析,按研究设计、人群特征和血管舒张剂类别对绝对和标准化平均差异(SMD)进行合并。
在 35 项报告了 57 项比较的研究中,收缩压降低(-4.13mmHg,-7.55 至-0.71,P=0.018),但 MFV 无变化(ΔMFV 1.11,置信区间-0.93 至 3.14,P=0.29,23 项比较)。基础疾病患者的 MFV 增加(3.41,0.24 至 6.57,P=0.04),而健康研究参与者的 MFV 无变化(-1.27,-5.18 至 2.64,P=0.68),不同的血管舒张药物类别无差异。所有研究均显示大脑搏动指数降低(Δ搏动指数-0.04,-0.07 至-0.02,P=0.001;Δ搏动指数-SMD-0.32,-0.47 至-0.16,P<0.001),但报告单次药物剂量反应的研究除外(Δ搏动指数 0.00,-0.09 至-0.08,P=0.93)。尽管存在报告和发表偏倚的证据,但血管舒张剂确实明显降低了 CBF(CBF-SMD-0.24,-0.46 至-0.02,P=0.03),并显著增加了脑血管反应性-SMD(0.48,0.13-0.83,P=0.007)。
尽管降低了 SBP,但血管舒张剂并没有显著降低 CBF 的绝对值,但改善了脑血管的搏动性和反应性,这表明在预防中风和脑小血管疾病方面具有潜在的治疗价值。